Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction

被引:315
作者
Maisel, AS
Koon, J
Krishnaswamy, P
Kazenegra, R
Clopton, P
Gardetto, N
Morrisey, R
Garcia, A
Chiu, A
De Maria, A
机构
[1] Vet Affairs Med Ctr, Div Cardiol, San Diego, CA 92161 USA
[2] Vet Affairs Med Ctr, Dept Med, San Diego, CA 92161 USA
[3] Univ Calif San Diego, San Diego, CA 92103 USA
关键词
D O I
10.1067/mhj.2001.113215
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Although echocardiography is an important tool for making the diagnosis of left ventricular (LV) dysfunction, the cost of this procedure limits its use as a routine screening tool for this purpose. Brain natriuretic peptide (BNP) accurately reflects ventricular pressure, and preliminary studies have found it to be highly sensitive and highly specific in diagnosing congestive heart failure in the emergency department. We hypothesized that BNP might therefore be useful as a screening tool before echocardiography in patients with suspected LV dysfunction. Methods subjects included patients referred for echocardiography to evaluate the presence or absence of LV dysfunction. Patients with known IV dysfunction were excluded from analysis. BNP was measured by a point-of-care immunoassay (Biosite Diagnostics, San Diego, Calif), The results of BNP levels were blinded from cardiologists making the assessment of LV function. Patients were divided into those with normal ventricular function, abnormal systolic ventricular function, abnormal diastolic function, and evidence of both systolic and diastolic dysfunction. Results Two hundred patients in whom LV function was unknown were studied. In the 105 patients (53%) whose ventricular function was subsequently determined to be normal by echocardiography, BNP levels averaged 37 +/- 6 pg/mL. This was significantly less than in those patients with either ultimate diastolic dysfunction (BNP 391 +/- 89 pg/ml (P < .001) or systolic dysfunction (BNP 572 +/- 115 pg/ml (P < .001). A receiver-operator characteristic curve showing the sensitivity and specificity of BNP against the echocardiography diagnosis revealed the area under the curve (accuracy) was 0.95. At a BNP level of 75 pg/ml was 98% specific for detecting the presence or absence of LV dysfunction by echocardiography. Conclusions A simple, rapid test for BNP, which can be performed at the bedside or in the clinic, can reliably predict the presence or absence of LV dysfunction on echocardiogram. The data indicate that BNP may be on excellent screening tool for LV dysfunction and may, in fact, preclude the need For echocardiography in many patients.
引用
收藏
页码:367 / 374
页数:8
相关论文
共 46 条
[1]   Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure [J].
Bristow, MR ;
Gilbert, EM ;
Abraham, WT ;
Adams, KF ;
Fowler, MB ;
Hershberger, RE ;
Kubo, SH ;
Narahara, KA ;
Ingersoll, H ;
Krueger, S ;
Young, S ;
Shusterman, N .
CIRCULATION, 1996, 94 (11) :2807-2816
[2]   Natriuretic peptides - Relevance in cardiovascular disease [J].
Cheung, BMY ;
Kumana, CR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (23) :1983-1984
[3]   Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure [J].
Clerico, A ;
Iervasi, G ;
Del Chicca, MG ;
Emdin, M ;
Maffei, S ;
Nannipieri, M ;
Sabatino, L ;
Forini, F ;
Manfredi, C ;
Donato, L .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1998, 21 (03) :170-179
[4]   A COMPARISON OF ENALAPRIL WITH HYDRALAZINE ISOSORBIDE DINITRATE IN THE TREATMENT OF CHRONIC CONGESTIVE-HEART-FAILURE [J].
COHN, JN ;
JOHNSON, G ;
ZIESCHE, S ;
COBB, F ;
FRANCIS, G ;
TRISTANI, F ;
SMITH, R ;
DUNKMAN, WB ;
LOEB, H ;
WONG, ML ;
BHAT, G ;
GOLDMAN, S ;
FLETCHER, RD ;
DOHERTY, J ;
HUGHES, CV ;
CARSON, P ;
CINTRON, G ;
SHABETAI, R ;
HAAKENSON, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (05) :303-310
[5]   PLASMA NOREPINEPHRINE AS A GUIDE TO PROGNOSIS IN PATIENTS WITH CHRONIC CONGESTIVE HEART-FAILURE [J].
COHN, JN ;
LEVINE, TB ;
OLIVARI, MT ;
GARBERG, V ;
LURA, D ;
FRANCIS, GS ;
SIMON, AB ;
RECTOR, T .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 311 (13) :819-823
[6]   Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care [J].
Cowie, MR ;
Struthers, AD ;
Wood, DA ;
Coats, AJS ;
Thompson, SG ;
PooleWilson, PA ;
Sutton, GC .
LANCET, 1997, 350 (9088) :1349-1353
[7]  
DAO Q, IN PRESS J AM COLL C
[8]   PLASMA BRAIN NATRIURETIC PEPTIDE IN ASSESSMENT OF ACUTE DYSPNEA [J].
DAVIS, M ;
ESPINER, E ;
RICHARDS, G ;
BILLINGS, J ;
TOWN, I ;
NEILL, A ;
DRENNAN, C ;
RICHARDS, M ;
TURNER, J ;
YANDLE, T .
LANCET, 1994, 343 (8895) :440-444
[9]  
DEVEREUX RB, 1987, HYPERTENSION, V9, P97
[10]  
DRUMHOLZ HM, 1994, J AM COLL CARDIOL, V24, P125